On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
- 14 September 2014
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (18) , 4861-4872
Abstract
Purpose: Chronic lymphocytic leukemia (CLL) remains incurable despite advances in therapy. In this study, we characterize the effect of nicotinamide phosphoribosyltransferase (NAMPT) inhibition by FK866 in primary CLL cells from patients with various clinical prognostic markers. Experimental Design: CLL cells were treated with FK866 to assess viability by Annexin V/PI staining. Functional analysis of FK866 included time- and concentration-dependent evaluation of cellular NAD, ATP, mitochondrial membrane potential (MMP), reactive oxygen species (ROS), and apoptotic signaling. Chemosensitization potential by FK866 to fludarabine was also assessed. Prognostic markers were correlated with drug response. Results: FK866 induced CLL cell death by depleting cellular NAD content by day 1, followed by a drop in ATP on day 2. We observed loss of MMP, ROS increase, and induction of apoptotic signaling at day 3. On-target activity of FK866 was confirmed by NAD-mediated rescue of NAD and ATP loss, apoptotic signaling, and viability. The response to FK866 was independent of most prognostic markers. Higher doses were required with short lymphocyte doubling time and positive CD38 status, whereas CLL cells resistant to fludarabine in vitro and from patients with del17p13.1 were equally sensitive to FK866. FK866 did not upregulate the p53-target p21, nor did the p53 activator Nutlin improve FK866-mediated cell death. Furthermore, fludarabine and FK866 were synergistic at clinically relevant concentrations. Conclusions: NAMPT inhibition by FK866 may be a potential treatment for CLL, including patients with del17p13.1 or other high-risk features. FK866 may complement standard agents to enhance their efficacy and/or allow dose reduction for improved tolerability. Clin Cancer Res; 20(18); 4861–72. ©2014 AACR.Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Pharmacological Effects of Exogenous NAD on Mitochondrial Bioenergetics, DNA Repair, and ApoptosisMolecular Pharmacology, 2011
- Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia CellsPLOS ONE, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Regulation of cancer cell metabolismNature Reviews Cancer, 2011
- The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling PathwaysEndocrine Reviews, 2010
- Nampt: linking NAD biology, metabolism and cancerTrends in Endocrinology & Metabolism, 2009
- The Critical Role of the Class III Histone Deacetylase SIRT1 in CancerCancer Research, 2009
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cellsBlood, 2007
- On the Origin of Cancer CellsScience, 1956